Breaking News

INC Research Launches Catalyst Program

February 19, 2016

Aims to enhance clinical research and results

INC Research has launched its Catalyst program aimed at strengthening collaborations with clinical research sites worldwide, and enhancing patient focus and optimizing study delivery to drive improved predictability of trials and reduce development timelines. 
The program includes the Catalyst Site Network, a group of high-performing, strategic and therapeutic sites, and the Catalyst Community, an online support forum representing a broader range of sites, all focused on enhancing collaborations with clinical research sites to drive improvement and development of best practices. The program also aims to reduce variability and increase predictability of clinical trials.
INC Catalyst Sites will have the opportunity to participate in an increased volume of clinical trials, with a dedicated manager supporting the site and facilitating optimal matching to protocols. Participation in the Catalyst Site network is by invitation only and will initially focus on oncology and vaccine sites in the U.S. and Asia/Pacific region.The Catalyst Community is open to all sites and is planned for launch in 2Q16.

“Sites play an essential role in bringing new therapies to market for patients,” said Clare Grace, Ph.D., vice president, Site and Patient Access. “By involving them early on and making them a partner in the clinical development process, studies start more quickly and run more predictably, enabling INC to better deliver on the needs of our customers and ultimately accelerate the delivery of new therapies to patients. The launch of our Catalyst program underscores INC’s continued efforts and commitment to strengthening our connections with this critical stakeholder group to drive innovation in clinical research.”
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems